0001209191-21-041058.txt : 20210616
0001209191-21-041058.hdr.sgml : 20210616
20210616182007
ACCESSION NUMBER: 0001209191-21-041058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210615
FILED AS OF DATE: 20210616
DATE AS OF CHANGE: 20210616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40475
FILM NUMBER: 211022698
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Janux Therapeutics, Inc.
CENTRAL INDEX KEY: 0001817713
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822289112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-750-4700
MAIL ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-15
0
0001817713
Janux Therapeutics, Inc.
JANX
0001357522
Thompson Peter A.
C/O JANUX THERAPEUTICS, INC.
11099 N. TORREY PINES ROAD, SUITE 290
LA JOLLA
CA
92037
1
0
0
0
Common Stock
2021-06-15
4
C
0
1348421
A
1348421
I
See footnotes
Common Stock
2021-06-15
4
C
0
823742
A
2172163
I
See footnotes
Common Stock
2021-06-15
4
P
0
588203
17.00
A
2760366
I
See footnotes
Common Stock
2021-06-15
4
C
0
164748
A
164748
I
See footnotes
Common Stock
2021-06-15
4
P
0
117650
17.00
A
282398
I
See footnotes
Series A Convertible Preferred Stock
2021-06-15
4
C
0
1052632
D
Common Stock
1348421
0
I
See footnotes
Series B Convertible Preferred Stock
2021-06-15
4
C
0
643046
D
Common Stock
823742
0
I
See footnotes
Series B Convertible Preferred Stock
2021-06-15
4
C
0
128609
D
Common Stock
164748
0
I
See footnotes
Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
The securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general
partner of OPI VIII and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and
Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to
have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl
L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. The Reporting Person is an employee of Advisors.
Each of Advisors, GP VIII, OrbiMed Genesis GP LLC ("Genesis GP"), and the Reporting Person disclaims beneficial ownership of the securities
reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of
its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of
such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares were purchased in the Issuer's initial public offering.
The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Fund"). Genesis GP is the general partner of Genesis Fund
and Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and Advisors may be deemed to have voting
and investment power with respect to the shares held by Genesis Fund and as a result may be deemed to have beneficial ownership of such
shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and
Jonathan T. Silverstein. The Reporting Person is an employee of Advisors.
/s/ Tighe Reardon, Attorney-in-Fact
2021-06-16